Popular on s4story
- Key Burns Releases New Children's Book - Princess Michaela and the Orange Dragon
- Author Samuel C. A.'s New Book Receives A Warm Literary Welcome
- Grammy Nominated Artist "Special Request Ft Rey T", They're Back And Coming With A Vengeance!
- A New Day for Fixed Wireless Access (FWA), BEC Unveils the AirConnect® 8243 High-Power 5G mmWave Outdoor Router
- New Book - A Little Boy on Ramree Island By Aung Z. and Jill Mong
- TOKYO SKYTREE TOWN will host Spring Events
- "Not Going Quietly" Wins Cinema for Peace Award for Political Film of the Year 2022 in Berlin
- Char Ferguson Of Just Call The I.T. Guy, Honored As The Wylie TX 2023 Local Business Person Of The Year
- Author Kristi Strong's Thrilling Debut Novel
- Orbex Awarded "Most Transparent Forex Broker, 2023"
Similar on s4story
- Jennifer S. Wilkov Finalizes Lineup for the 2023 April Speak Up Women Conference
- Doug Brownridge Joins STS Capital Partners
- Cash Depot Appoints Tony Gaines as Chief Revenue Officer and Brand Ambassador
- Eddie Turner is Recognized as the #9 Motivational Speaker in the World By Global Gurus!
- Wohler releases out-of-band configuration tools for Riedel 2110 SFP's
- Levinger Regens Announces New Initiative to Improve Hydrogen Carbon Intensity
- Expert tip: Private Jet Engine Maintenance Program - Pros and Cons for Preowned Jet Buyers
- .Store Domains launches Elevate.store – a free-to-use platform for online sellers with deals on business tools
- GP GLOBAL GROUP Secures $18M Sale of Shoppes at 41st Street Retail Plaza in Doral, Florida, with $11.5M CMBS Loan Assumption
- Rewilding Ireland with Lord Dunsany and IrishTrees
CATALENT DEADLINE ALERT: Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $100,000 In Catalent To Contact Him Directly To Discuss Their Options
S For Story/10579587
NEW YORK, March 18, 2023 /PRNewswire/ -- Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Catalent, Inc. ("Catalent" or the "Company") (NYSE: CTLT) and reminds investors of the April 25, 2023 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company.
If you suffered losses exceeding $100,000 investing in Catalent stock or options between August 30, 2021 and October 31, 2022, both dates inclusive (the "Class Period") and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310). You may also click here for additional information: www.faruqilaw.com/CTLT.
There is no cost or obligation to you.
Faruqi & Faruqi is a leading minority and Woman-owned national securities law firm with offices in New York, Pennsylvania, California and Georgia.
Catalent is a multinational corporation that manufactures and packages drugs into delivery devices fit for human consumption (i.e., pre-filled syringes, vials, pills, etc.) pursuant to long-term supply contracts with pharmaceutical companies. Catalent directly sells these products to pharmaceutical companies which later sell them through the supply chain to healthcare providers (i.e., hospitals, clinics, etc.), which administer them to patients, who are the end consumers. Catalent's vaccine manufacturing business initially benefitted from the COVID-19 pandemic, causing its stock price to soar to record highs.
More on S For Story
The Complaint alleges that by mid-2021, when COVID-related work dropped off, Defendants engaged in accounting and channel stuffing schemes to pad the Company's revenues. These schemes gave Catalent the appearance of continued growth, causing its stock price to reach record highs. Meanwhile, to support these schemes and keep pace with its lofty growth targets, Catalent was cutting corners on safety and control procedures at key production facilities. By late 2022, Catalent reported significant sales declines and excess inventory throughout its supply chain. As a result, Catalent stock dropped to pre-COVID levels causing substantial losses to its investors as they learned that Catalent's early-COVID revenues were never sustainable, and its Class Period revenues were the product of securities fraud.
The Complaint further alleges that statements made by Defendants throughout the Class Period were materially false and misleading when made because they misrepresented or failed to disclose the following adverse facts, which were known to Defendants or recklessly disregarded by them: (a) Catalent materially overstated its revenue and earnings by prematurely recognizing revenue in violation of U.S. Generally Accepted Accounting Principles ("GAAP"); (b) Catalent had material weaknesses in its internal control over financial reporting related to revenue recognition; (c) Catalent falsely represented demand for its products while it knowingly sold more product to its direct customers than could be sold to healthcare providers and end consumers; (d) Catalent disregarded regulatory rules at key production facilities in order to rapidly produce excess inventory that was used to pad the Company's financial results through premature revenue recognition in violation of GAAP and/or stuffing its direct customers with this excess inventory; and (e) as a result of the foregoing, Defendants lacked a reasonable basis for their positive statements about the Company's financial performance, outlook, and regulatory compliance during the Class Period.
More on S For Story
The court-appointed lead plaintiff is the investor with the largest financial interest in the relief sought by the class who is adequate and typical of class members who directs and oversees the litigation on behalf of the putative class. Any member of the putative class may move the Court to serve as lead plaintiff through counsel of their choice, or may choose to do nothing and remain an absent class member. Your ability to share in any recovery is not affected by the decision to serve as a lead plaintiff or not.
Faruqi & Faruqi, LLP also encourages anyone with information regarding Catalent's conduct to contact the firm, including whistleblowers, former employees, shareholders and others.
Attorney Advertising. The law firm responsible for this advertisement is Faruqi & Faruqi, LLP (www.faruqilaw.com). Prior results do not guarantee or predict a similar outcome with respect to any future matter. We welcome the opportunity to discuss your particular case. All communications will be treated in a confidential manner.
SOURCE Faruqi & Faruqi, LLP
If you suffered losses exceeding $100,000 investing in Catalent stock or options between August 30, 2021 and October 31, 2022, both dates inclusive (the "Class Period") and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310). You may also click here for additional information: www.faruqilaw.com/CTLT.
There is no cost or obligation to you.
Faruqi & Faruqi is a leading minority and Woman-owned national securities law firm with offices in New York, Pennsylvania, California and Georgia.
Catalent is a multinational corporation that manufactures and packages drugs into delivery devices fit for human consumption (i.e., pre-filled syringes, vials, pills, etc.) pursuant to long-term supply contracts with pharmaceutical companies. Catalent directly sells these products to pharmaceutical companies which later sell them through the supply chain to healthcare providers (i.e., hospitals, clinics, etc.), which administer them to patients, who are the end consumers. Catalent's vaccine manufacturing business initially benefitted from the COVID-19 pandemic, causing its stock price to soar to record highs.
More on S For Story
- CSC Motorcycles Announces New Twin Cylinder 650cc Sport Touring Model
- Vincenzo Sannipoli Announces the Release of Sulla vetta del tubo
- Cargill joins Selerant on stage at American Food Innovate 2023
- The In-N-Out Burger Financial Planning Story
- Cash Depot Appoints Tony Gaines as Chief Revenue Officer and Brand Ambassador
The Complaint alleges that by mid-2021, when COVID-related work dropped off, Defendants engaged in accounting and channel stuffing schemes to pad the Company's revenues. These schemes gave Catalent the appearance of continued growth, causing its stock price to reach record highs. Meanwhile, to support these schemes and keep pace with its lofty growth targets, Catalent was cutting corners on safety and control procedures at key production facilities. By late 2022, Catalent reported significant sales declines and excess inventory throughout its supply chain. As a result, Catalent stock dropped to pre-COVID levels causing substantial losses to its investors as they learned that Catalent's early-COVID revenues were never sustainable, and its Class Period revenues were the product of securities fraud.
The Complaint further alleges that statements made by Defendants throughout the Class Period were materially false and misleading when made because they misrepresented or failed to disclose the following adverse facts, which were known to Defendants or recklessly disregarded by them: (a) Catalent materially overstated its revenue and earnings by prematurely recognizing revenue in violation of U.S. Generally Accepted Accounting Principles ("GAAP"); (b) Catalent had material weaknesses in its internal control over financial reporting related to revenue recognition; (c) Catalent falsely represented demand for its products while it knowingly sold more product to its direct customers than could be sold to healthcare providers and end consumers; (d) Catalent disregarded regulatory rules at key production facilities in order to rapidly produce excess inventory that was used to pad the Company's financial results through premature revenue recognition in violation of GAAP and/or stuffing its direct customers with this excess inventory; and (e) as a result of the foregoing, Defendants lacked a reasonable basis for their positive statements about the Company's financial performance, outlook, and regulatory compliance during the Class Period.
More on S For Story
- One Maryland Family: A Microcosm of America's History
- Sip Social Co. Partners With Apé Canada For Supply Of Piaggio Apé's
- Arizona Author's Title Tapped as One of Thirty Best
- "The Solutionists" is the Call-To-Action for Business Leaders to Become More Purpose-Driven
- New Self-Help Book - The Mindset Game By Matthew Lawrence Scigousky
The court-appointed lead plaintiff is the investor with the largest financial interest in the relief sought by the class who is adequate and typical of class members who directs and oversees the litigation on behalf of the putative class. Any member of the putative class may move the Court to serve as lead plaintiff through counsel of their choice, or may choose to do nothing and remain an absent class member. Your ability to share in any recovery is not affected by the decision to serve as a lead plaintiff or not.
Faruqi & Faruqi, LLP also encourages anyone with information regarding Catalent's conduct to contact the firm, including whistleblowers, former employees, shareholders and others.
Attorney Advertising. The law firm responsible for this advertisement is Faruqi & Faruqi, LLP (www.faruqilaw.com). Prior results do not guarantee or predict a similar outcome with respect to any future matter. We welcome the opportunity to discuss your particular case. All communications will be treated in a confidential manner.
SOURCE Faruqi & Faruqi, LLP
Filed Under: Business
0 Comments
Latest on S For Story
- Cookbook Passion – Available Now from Histria Books
- Tupac Behind Bars – Available Now from Histria Books
- One Day children's book is a powerful book that empowers children, parents, and families
- .Store Domains launches Elevate.store – a free-to-use platform for online sellers with deals on business tools
- In Celebration of Women's History Month, the YMCA of the Rockies Hosts Famed Couple and Acclaimed Authors, Cheri and Tracey Syphax
- GP GLOBAL GROUP Secures $18M Sale of Shoppes at 41st Street Retail Plaza in Doral, Florida, with $11.5M CMBS Loan Assumption
- HLN's Immunization Calculation Engine (ICE) is continually updated to support new COVID-19 recommendations
- Wayne M. Bailey Releases New Science Fiction Novel - The Mars Migration
- Words N More Creative, LLC Launches Niche Magazine Artisan Joy
- Rewilding Ireland with Lord Dunsany and IrishTrees
- The Tokyo Rebels Announces the Release of Their Groundbreaking Whitepaper
- Armadillos with Benefits™ - PicPocket-Labs, Inc. details its plans/roadmap at SxSW for combining "location-based NFTs" and loyalty programs
- Never give up your dream: If you can dream it, you can do it
- A Field Guide for Preventing and Treating Cognitive Decline paperback
- Microsoft-Backed HRtech Startup ZingHR Invests In SaaS Startup LokiBots
- World Sleep Day, why do we celebrate?
- HGR Alcohol Detox Centers in San Diego Accepts Most Health Insurances
- ShopCHARLI.com Launches Online Store With a Hot New Spring Collection that Doesn't Miss
- Congressman Mark Alford endorsed by Veterans for Trump on his 2024 re-election
- February 2023 Financial Market Review